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license (http://creativedecline. The Aging and Cognitive Health Evaluation in Elders study is a multicenter randomized
controlled trial to determine efficacy of hearing treatment in reducing cognitive decline in older
adults. Clinicaltrials.gov Identifier: NCT03243422.
Methods: Eight hundred fifty participants without dementia aged 70 to 84 years with mild-to-
moderate hearing impairment recruited from four United States field sites and randomized 1:1 to a
best-practices hearing intervention or health education control. Primary study outcome is 3-year
change in global cognitive function. Secondary outcomes include domain-specific cognitive decline,
incident dementia, brain structural changes on magnetic resonance imaging, health-related quality of
life, physical and social function, and physical activity.
Results: Trial enrollment began January 4, 2018 and is ongoing.
Discussion: When completed in 2022, Aging and Cognitive Health Evaluation in Elders study
should provide definitive evidence of the effect of hearing treatment versus education control on
cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment.thor. Tel.:11-410-955-0491; Fax:11-410-614-9625.
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Peripheral hearing impairment, as measured with pure
tone audiometry, has been shown in recent population-
based observational studies to be strongly and consistently
related to accelerated cognitive decline [1] and increased de-
mentia risk in older adults [2]. Hypothesized pathways un-
derlying this association include effects of distorted
peripheral encoding of sound on cognitive load, changes in
brain structure/function, and/or reduced social engagement
[3]. Importantly, these pathways may be modifiable with
comprehensive hearing treatment and rehabilitation. Two-
thirds of adults older than 70 years have a clinically mean-
ingful hearing impairment that may affect daily communica-
tion [4,5]. Given this high prevalence and its strong
association with incident dementia, if hearing loss is
causally related to dementia, it is estimated that up to 9%
of dementia cases in the world could potentially be
prevented with hearing treatment and rehabilitation [2].
However, hearing aids remain grossly underutilized—less
than 20% of adults with hearing impairment in the United
States [6] use a hearing aid, with similar low utilization pat-
terns in other comparable countries [7].
Most observational studies suggest a trend associating
self-reported hearing aid use with better cognitive function
[8–10]. However, data on key variables (e.g., years of
hearing aid use, adequacy of hearing aid fitting, and
rehabilitation) that would affect the success of hearing
treatment—and therefore any observed association—have
not been available in these studies [11]. In addition, results
from observational studies should be interpreted with
caution as individuals who choose to use a hearing aid likely
differ significantly from individuals who do not in both
measured and unmeasured factors that may impact cognition
(e.g., socioeconomic status, health-seeking behaviors).
Consequently, determining whether hearing rehabilitative
strategies could delay cognitive decline will likely never
be answered definitively from observational studies alone,
and therefore will require a randomized trial.
Here we describe the study design of the Aging and
Cognitive Health Evaluation in Elders (ACHIEVE) random-
ized controlled trial, a large multicenter randomized trial de-
signed to determine efficacy of hearing treatment in delaying
cognitive decline in older adults. ACHIEVE is a study of 850
older adults without dementia aged 70 to 84 years with mild-
to-moderate hearing impairment randomized 1:1 to a best-
practices hearing intervention or successful aging health ed-
ucation control. The ACHIEVE trial is partially nested
within the larger observational prospective Atherosclerosis
Risk in Communities (ARIC) Study [12].2. Study objectives
The primary objective of the ACHIEVE study is to deter-
mine efficacy of a best-practices hearing rehabilitative inter-
ventionversus a successful aging health education control on
rates of 3-year decline in a global cognitive function in 70 to
84 year-old well-functioning older adults without dementia
who have mild-to-moderate hearing impairment.
Secondary cognitive outcomes include domain-specific
cognitive declines (memory, executive function, and lan-
guage) and a composite outcome of adjudicated incident
dementia, mild cognitive impairment, or a 3-point
decline in the Mini-Mental State Examination (MMSE)
[13]. Other secondary outcomes include brain structure
on magnetic resonance imaging (MRI), health-related
quality of life, physical and social function, and physical
activity.3. Methods
3.1. ACHIEVE design, participants, and setting
ACHIEVE is a randomized, controlled multicenter supe-
riority trial of 850 older adults with two parallel groups
(best-practices hearing intervention vs. successful aging
health education control) and a primary end point of 3-
year change in global cognitive function. Stratified random-
ization is performed as permuted block randomization with a
1:1 allocation. Four ACHIEVE intervention visits occur
within 8 to 10 weeks (one every 1–3 weeks) postrandomiza-
tion with booster sessions every 6months postrandomization
up to 30 months. ACHIEVE clinic visits occur at 6 months
(limited assessment battery and first intervention booster
session) and annually for 3 years (Table 1). Clinicaltrials.
gov identifier: NCT03243422.
Approximately half of ACHIEVE participants will be re-
cruited from the ARIC cohort study, and half de novo from
the surrounding communities. ARIC is a mostly biracial pro-
spective study of 15,792men and women aged 45 to 64 years
in 1987 to 1989 from four US communities: Forsyth County,
NC; Jackson, MS; selected suburbs of Minneapolis, MN;
and Washington County, MD.
The ARIC Data Coordinating Center at the University of
North Carolina also coordinates ACHIEVE data manage-
ment. ACHIEVE and ARIC clinic visits are coordinated to
maximize efficiency and minimize participant burden.
Informed consent is obtained from all participants at the
baseline visit, and study procedures are approved by the
Institutional Review Board governing each field center.
Table 1
Schedule of enrollment, interventions, and assessments: the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial
Timepoint
Study period
Enrollment Allocation Postallocation Close-out
230 to 21 d Day 0 1–3 wk 3–5 wk 6–8 wk 8–10 wk 6 mo 12 mo 18 mo 24 mo 30 mo 36 mo
Enrollment
Eligibility screen X X
Informed consent X X
Demographics X





Hearing X X X X X (booster) X (booster) X (booster) X (booster) X (booster)
Successful aging X X X X X (booster) X (booster) X (booster) X (booster) X (booster)
Assessments
Audiometric battery
Air conduction audiometry X X X X
Bone conduction audiometry X X* X* X*
Tympanometry X X X X
Word recognition in quiet X X X X
Quick speech-in-noise (unaided) X X X X
Cognition (primary outcome)
Speech understanding X X X X
MMSE X X X X X X X
Delayed word recall X X X X
Digit symbol substitution X X X X
Incidental learning X X X X
Trail making parts A and B X X X X
Logical memory X X X X
Digit span backward X X X X
Boston Naming Test X X X X
Word fluency X X X X
Animal naming X X X X
Secondary outcomes X X X
Clinical dementia rating X X X X
Dementia/MCI evaluation X* X* X* X*
Brain MRIy X X
Qualifying adverse events X X X X X X X X X X X
CES-D Scale X X X X X
Physical activity survey X X X X
HHIE-screening X X X X X
RAND-36 health survey X X X X X
Cohen Social Network Index X X X X X
UCLA Loneliness Scale X X X X X
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Eligibility criteria are designed to identify community-
dwelling older adults with mild-to-moderate hearing impair-
ment who are at risk for cognitive decline and may possibly
benefit from hearing treatment and rehabilitation. Partici-
pants are prescreened by telephone and complete a screening
evaluation at a follow-up clinic visit (Fig. 1).
3.2.1. Inclusion criteria
ACHIEVE participants are adults aged 70 to 84 years
with untreated adult-onset bilateral hearing impairment,
defined as a better-hearing ear 4-frequency pure tone
average (PTA, average of the threshold levels for the pure
tone frequencies of 0.5, 1, 2, and 4 kHz in the better-
hearing ear) 30 and ,70 dB hearing level who do not
have dementia (MMSE 23 if high school degree or less
and25 if some college or more) [14]. Consistent with hear-
ing impairment that is likely to benefit from amplification,
participants have a Word Recognition in Quiet score
60% correct in the better-hearing ear. Participants are
community-dwelling with plans to remain in the area during
the study period and are fluent English speakers (Table 2).
3.2.2. Exclusion criteria
Exclusion criteria include prior dementia diagnosis, self-
reported difficulty in2 activities of daily living [15], vision
impairment that may interfere with cognitive testing (worse
than 20/60 with correction on Minnesota Near Vision Card),
medical contraindication to hearing treatment (e.g., draining
ear), untreatable conductive hearing impairment (difference
in air audiometry and bone audiometry, or “air-bone gap,”
.15 dB in two or more contiguous frequencies in both
ears that cannot be medically resolved), or unwillingness
to regularly wear hearing aids (Table 2).
3.3. Recruitment
ACHIEVE recruitment began January 4, 2018 with
completion anticipated May 2019. Field sites employ site-
specific strategies that have demonstrated prior success
with recruitment of older adults, including use of established
research registries, targeted advertisements in aging-related
publications and other media, established field site relation-
ships with local churches/retirement centers, mass mailings,
and so forth.
3.4. Randomization
The ACHIEVE Data Coordinating Center oversees the
randomization process and generated the allocation
schedule. After final determination of eligibility and confir-
mation of informed consent, participants are randomized 1:1
to the hearing intervention or to the successful aging educa-
tion control. To ensure balance between the treatment
groups, participants are randomized in permuted order
blocks of varying sizes within strata defined by severity of
J.A. Deal et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 499-507 503hearing impairment—mild (PTA 30 and,40 dB) or mod-
erate to moderate (PTA40 and,70 dB), participant status
(ARIC participant or recruited de novo), and by field site.
Field center staff are masked to block size.3.5. Masking
Neither study participants nor study technicians collect-
ing outcome data can feasibly be masked (blinded) to
randomization status. Precautions to minimize potential
bias resulting from the lack of masking include use of an es-
tablished attention control intervention (i.e., to optimize
participant retention across both study arms) [16]; masking
of participants to the study hypothesis; use of standardized
protocols for training of data collectors and assessment of
study outcomes; lack of access to cognitive testing results
from prior study visits for data collectors and study coordi-
nators to avoid unintentional and possibly unconscious
bias by study staff during data collection; and masking of
accumulating trial data from ACHIEVE principal investiga-
tors, coinvestigators, and key project staff.3.6. Study interventions
Participants are randomized 1:1 to a best-practices hear-
ing intervention or to a successful aging health education
control. Both interventions were successfully piloted for
feasibility in a 6-month 40-person ACHIEVE-Pilot study
conducted at the ARIC Washington County site with no
treatment-related adverse events [17].
3.6.1. Ethics of the use of a health education control
Use of a health education control is deemed ethical, as
currently there is no established usual or standard-of-care
for reducing cognitive decline in older adults without de-
mentia [18]. There is also no established usual care for the
management of hearing loss in older adults; a recent report
from the United States Preventative Services Task Force
found insufficient evidence to recommend hearing loss
screening or treatment for adults 50 years or older [19]. Par-
ticipants in each treatment arm will be offered and provided
the other study intervention at the conclusion of the trial.
3.6.2. Best-practices hearing intervention
Developed at the University of South Florida, the main
objective of the hearing intervention is to minimize activity
limitations and participation restrictions due to hearing
impairment. Using evidence-based best practices [20], the
intervention includes individual needs assessment, goal-
setting [21], engagement in shared-informed decision-mak-
ing, and the development of self-management abilities for
hearing loss and communication in real-world settings
(e.g., understanding hearing loss, realistic expectations,
communicating in background noise, using communication
strategies and tactics, and resources for adults with hearing
loss and their communication partners).The hearing intervention consists of four 1-hour sessions
with a research audiologist held every 1 to 3weeks postrandom-
ization. Participants receivebilateral receiver-in-the-canal hear-
ing aids fit to prescriptive targets using real-ear measures and
other hearing assistive technologies to pair with the hearing
aids (e.g., devices to stream cell phones and television, remote
microphones to directly access other speakers in difficult
listening environments). The intervention includes systematic
orientation and instruction in device use and hearing “toolkit”
materials for self-management and communication strategies.
Reinstruction in use of devices and hearing rehabilitative
strategies is provided during booster visits held every
6 months postrandomization. Unscheduled interim visits
may also be sporadically required (e.g., hearing aid malfunc-
tion), and these visits to troubleshoot hearing aids are sched-
uled as needed if the issue cannot be resolved with a
telephone conversation.
3.6.3. Communication partners for participants
randomized to the hearing intervention
Communication partners or adults who communicate
with ACHIEVE participants on a daily or near-daily basis
(e.g., spouse) are often a key to successful intervention for
older adults with hearing impairment. Communication part-
ners for participants randomized to the hearing intervention
are invited to join the study and to contribute data related to
their own quality of life and their observations of the effects
of the hearing intervention on the participant. Communica-
tion partners are encouraged to attend hearing intervention
sessions as part of the intervention.
3.6.4. Successful aging health education control
intervention
The successful aging control follows the protocol andma-
terials developed for the 10 Keys to Healthy Aging [22], an
evidence-based interactive health education program for
older adults on topics relevant to chronic disease and
disability prevention, which has been previously imple-
mented in other trials [23,24]. It contains the most up-to-
date prevention guidelines available based on the current
recommendations from leading groups such as the United
States Preventive Services Task Force, Centers for Disease
Control, and National Academy of Sciences.
To control for general levels of staff and participant time
and attention, participants randomized to this group meet
individually with a certified health educator who administers
the program every 1 to 3 weeks for a total of four visits over
w2 to 3 months. Session content is tailored to each partici-
pant and includes a standardized didactic education compo-
nent as well as activities, goal-setting, and optional
extracurricular enrichment activities. To further enhance
retention and perceived benefit, each session also includes
a 5- to 10-minute upper body extremity stretching program
[25]. To match the contact schedule with the hearing inter-
vention and promote retention, participants return for
booster sessions semiannually.
Fig. 1. Participant screening and randomization: the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial. *Strata defined by severity
of hearing impairment, participant status (ARIC participant or recruited de novo), and field site.
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Table 1 summarizes ACHIEVE assessments. Although
study personnel collecting cognitive data cannot feasibly
be masked to participant intervention assignment, they are
masked to outcome data assessed at previous visits.
3.7.1. Primary outcome
The primary study outcome is the change from baseline to
year 3 in a global cognitive function factor score derived
from a full neuropsychological battery with tests represent-
ing multiple cognitive domains, including memory, lan-
guage, and executive function/attention (Table 1). Factor
scores are developed using a latent variable modelingapproach and have been previously used and validated in
the observational ARIC cohort [26]. Compared with other
summary measures, such as weighted averages (e.g.,
z-scores), the factor scores better account for measurement
error of individual tests and their relative difficulty [26]
and improve precision [27]. The neurocognitive battery is
collected at the baseline visit and annually thereafter for
3 years (Table 1).
Because ACHIEVE participants have mild-to-moderate
hearing impairment, a brief test is conducted before the neu-
rocognitive assessment to determine whether the participant
can adequately hear the examiner. Developed by coinvesti-
gators with neuropsychological expertise, this brief test, in
conjunction with a standardized protocol that includes
Table 2
Inclusion and exclusion criteria: the Aging and Cognitive Health Evaluation
in Elders (ACHIEVE) randomized trial
Criteria Description
Inclusion  Age 70–84 y
 Adult onset mild-to-moderate hearing impairment
[4-frequency better-hearing ear pure tone average
30 dB HL and ,70 dB HL]
 Cognitively-intact (MMSE 23 for high school de-
gree or less; 25 for some college or more)
 Speech recognition score .60% correct in the better-
hearing ear
 Plans to stay in the geographic area for study duration
 Community-dwelling
 Fluent English speaker
Exclusion  Self-reported disability in 2 activities of daily living
 Vision impairment (worse than 20/63 on Minnesota
Near Vision Card)
 Self-reported use of a hearing aid in the past 1 y
 Medical contraindication to use of hearing aids (e.g.,
draining ear)
 Unwilling to wear hearing aids on daily basis
 Conductive hearing impairment with air-bone gap
.15 dB in two or more contiguous frequencies in both
ears that cannot be resolved
Abbreviations: HL, hearing level; MMSE, Mini-Mental State Examina-
tion.
J.A. Deal et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 499-507 505face-to-face communication in a quiet room and presenta-
tion of both written and verbal testing instructions, ensures
sufficient access to the verbal test instructions and reduces
hearing impairment as a direct confound in the neurocogni-
tive testing and any measured efficacy signal for the hearing
(vs. successful aging) intervention.
3.7.2. Secondary outcomes
Key secondary outcomes include 3-year change in cognitive
domain-specific latent factor scores (memory, executive func-
tion, and language) and time until meeting a composite
outcome consisting of adjudicated incident dementia, mild
cognitive impairment, or a 3-point MMSE decline. Syndromic
diagnosis ofmild cognitive impairment or dementia is obtained
by standardized algorithms incorporating cognitive test scores,
cognitivedecline acrossprior studyvisits, and subject and infor-
mant interviews, followed by expert-adjudicated review [28].
Other secondary outcomes include brain structural char-
acteristics fromMRI (from a subsample) and functional out-
comes independently associated with hearing impairment,
including health-related quality of life, social factors (lone-
liness and social network), hospitalizations, falls, physical
function, and physical activity (Table 2).
3.7.3. Audiometric measures
All participants receive a full audiometric battery at
screening and at annual follow-up visits (Table 1). In partic-
ipants randomized to the hearing intervention, audiologic
outcomes to verify the intervention (e.g., hearing aid data
logging, real-ear measures, aided speech-in-noise) are gath-
ered semiannually beginning 6 months postrandomization.3.7.4. Covariates
Demographic factors, medical history, and other clinical
factors are collected at baseline and annually.Within 6months
of baseline, blood will be drawn for apolipoprotein E (APOE)
genotyping from non-ARIC participants; APOE ε4 status of
ARIC participants has already been established (Table 1).3.8. Statistical Considerations3.8.1. Sample size
We estimate a sample size of N 5 850 provides 90% po-
wer to detect a standardized effect size of 0.26 (80% power
for a standardized effect size of 0.23) for the difference be-
tween intervention groups in the mean change from baseline
in global cognition factor score at 3 years, based on a two-
sided t test and 5% type I error rate. These estimates account
for a conservative net total of 15% drop-in (uptake of hearing
aids in the control group) and dropout (discontinuation of
hearing aid use in the hearing intervention group).
3.8.2. Statistical methods
The primary analysis will compare change in the global
cognitive function factor score from baseline to year 3 in
the hearing intervention group versus the successful aging
health education control for the intent-to-treat population,
which includes all randomized subjects using amultiple impu-
tation analysis of covariance model with adjustment for age,
education (high school vs. .high school), an interaction
term between race and study site, baseline global cognition
factor score, baseline hearing loss, and participant recruitment
status (from ARIC or de novo from the community).
Because dropout due to dementia may bias (underesti-
mate) the relationship between intervention assignment
and cognitive change, for ACHIEVE participants who are
diagnosed with dementia during follow-up but do not attend
the year 3 clinic visit (and so are missing the year 3 cognitive
score), the missing year 3 cognitive scorewill be imputed us-
ing cognitive and other data from other ACHIEVE dementia
cases, as well as from non-ACHIEVE ARIC participants
who are diagnosed with dementia during a prespecified cal-
endar period aligning with the ACHIEVE follow-up time.
Other missing cognitive scores (e.g., missing for reasons
other than dementia diagnosis) will be imputed using
ACHIEVE data under the missing at random assumption.
For analysis of the key secondary outcomes, treatment
group comparisons will be adjusted for multiple compari-
sons using the Hochberg modification to the Bonferroni
method, so as to minimize the probability of a significant as-
sociation due to chance [29].
A secondary analysis of the primary outcome will be
completed for the per-protocol population, defined as a sub-
set of the intention-to-treat population who completed the 8-
to 10-week intervention period, had no hearing aid interven-
tion drop-in for the control group, and had no major protocol
deviations. Major protocol deviations include violations in
J.A. Deal et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 499-507506inclusion and exclusion criteria at enrollment and poor
compliancewith hearing aids for the hearing aid intervention
group, defined as subjects who discontinue hearing aid use at
any time during the study period.
An interim analysis to evaluate for sample-size re-estima-
tion based on conditional power will be performed after 66%
of subjects have completed the study. If the conditional po-
wer is in the promising zone [30], the sample size may be
increased up to 100% (850 additional participants) to in-
crease conditional power up to 80%. In the unexpected event
of low study enrollment, an assessment for futility may also
be performed at this interim.3.9. Safety monitoring
Study participation and exposure to the hearing aid inter-
vention is expected to have a low risk of participant adverse
events. To efficiently collect safety information relevant to
study participation, interventions, and procedures, detailed
information concerning a prespecified set of adverse events
and serious adverse events is collected and evaluated
throughout the trial, and is monitored by an independent
Data and Safety Monitoring Board.4. Discussion
Dementia is a global public health priority [31] and argu-
ably the greatest current challenge to health and social care
systems [2]. Novel approaches are urgently needed to reduce
risk of age-related cognitive decline in older adults [18]. The
ACHIEVE study is the first large multicenter randomized
controlled study to determine the efficacy of a best-
practices hearing intervention (vs. successful aging health
education control) for the delay of 3-year cognitive decline
in older adults aged 70 to 84 years with untreated mild-to-
moderate hearing impairment. Trial enrollment started on
January 4, 2018 and recruitment is ongoing.
Nesting of ACHIEVE within a large, well-characterized
multicenter observational study with over 30 years of
follow-upmaximizes both operational (dedicated study staff,
well-established protocols, and study staff-participant rela-
tionships) and scientific efficiency. Thirty years of prior lon-
gitudinal cognitive data are available for participants
recruited from ARIC, allowing for a secondary investigation
ofwhether the hearing rehabilitation intervention alters a par-
ticipant’s established prior trajectory of cognitive decline.
Brain MRI and amyloid measured by positron emission to-
mography are also available for a subset of these participants.
Whether hearing treatment and rehabilitation can delay
cognitive decline in at-risk older adults is unknown, but could
have substantial clinical, social, and public health impact as
evidenced by recent national initiatives focused on hearing
loss [7,32]. When completed in 2022, ACHIEVE should
provide definitive evidence of the effect of hearing
treatment on cognitive decline in community-dwelling older
adults with mild-to-moderate hearing impairment.Acknowledgments
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1. Systematic review: Literature review included tradi-
tional sources. Hearing impairment is highly preva-
lent and independently associated with cognitive
decline in observational studies. However, deter-
mining whether hearing rehabilitation delays cogni-
tive decline will likely never be answered
definitively from observational studies alone, there-
fore requiring a randomized trial.
2. Interpretation: The Aging and Cognitive Health Evalu-
ation in Elders (ACHIEVE) study is the first large,
multicenter randomized controlled study to determine
efficacy of a best-practices hearing intervention (vs.
successful aging health education control) for the delay
of 3-year cognitive decline in adults aged 70 to 84 years
with untreated hearing impairment. Enrollment began
January 2018 and is ongoing.
3. Future directions: Whether hearing treatment delays
cognitive decline in at-risk older adults is unknown, but
could have substantial clinical, social, and public health
impact. When completed in 2022, ACHIEVE should
provide definitive evidence of the effect of hearing
treatment on cognitive decline in community-dwelling
older adults with mild-to-moderate hearing impairment.
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